Home/Filings/4/0000950170-24-066144
4//SEC Filing

ROYSTON IVOR 4

Accession 0000950170-24-066144

CIK 0001061027other

Filed

May 28, 8:00 PM ET

Accepted

May 29, 7:07 PM ET

Size

19.8 KB

Accession

0000950170-24-066144

Insider Transaction Report

Form 4
Period: 2024-05-25
ROYSTON IVOR
DirectorCEO & President
Transactions
  • Exercise/Conversion

    Common Stock

    2024-05-25+25,219789,303 total
  • Exercise/Conversion

    Restricted Stock Units

    2024-05-2525,219100,876 total
    Common Stock (25,219 underlying)
Holdings
  • Common Stock

    (indirect: By Spouse)
    18,599
Footnotes (2)
  • [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.
  • [F2]One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

Issuer

Viracta Therapeutics, Inc.

CIK 0001061027

Entity typeother

Related Parties

1
  • filerCIK 0001026765

Filing Metadata

Form type
4
Filed
May 28, 8:00 PM ET
Accepted
May 29, 7:07 PM ET
Size
19.8 KB